AAV Vectors Using Stuffer Sequences to Expand Packaging Capacity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The packaging capacity of adeno-associated virus (AAV) vectors is limited to less than 5 kb, leading to inefficient packaging of oversized genomes and challenges in viral vector production and administration of gene therapies, which requires the development of non-coding regions to improve vector stability and infectivity.
Innovation Solution
The use of recombinant expression cassettes with stuffer polynucleotide sequences, such as those described by SEQ ID NO:1 and SEQ ID NO:5, to extend the transgene size and enhance the packaging efficiency of AAV vectors by flanking the heterologous gene with AAV inverted terminal repeats (ITRs) and including regulatory elements like promoters and polyA signals.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If the transgene size is increased to improve therapeutic utility, then the packaging capacity is exceeded, but the vector stability and infectivity are compromised
Solution Approach 1:
The patent changes the nucleotide sequence parameters of non-coding regions (stuffer sequences) to optimize packaging capacity. By carefully selecting and modifying stuffer sequence lengths and compositions, the total genome size is adjusted to fit within AAV packaging limits while maintaining vector stability and infectivity.
Solution Approach 2:
The patent creates composite vector genomes by combining coding sequences (transgenes) with non-coding stuffer sequences. This composite structure allows the vector to accommodate larger therapeutic genes by filling space with strategically designed stuffer sequences that maintain packaging capacity and vector functionality.
2Quantity of substance
If the genome size is enlarged to accommodate larger transgenes, then the packaging capacity is exceeded, but the vector infectivity and stability are reduced
Solution Approach 1:
The patent optimizes genome size parameters by adjusting stuffer sequence lengths and compositions. This allows the vector to accommodate larger transgenes while maintaining infectivity through careful parameter control to stay within packaging capacity limits.
Solution Approach 2:
The stuffer sequences act as intermediary elements that fill space between the transgene and the packaging capacity limit. These non-coding sequences mediate the relationship between transgene size and packaging capacity, allowing larger transgenes to be packaged without compromising vector infectivity.
3Adaptability or versatility
If non-coding stuffer sequences are added to extend transgene size, then the packaging capacity is optimized, but the vector complexity increases
Solution Approach 1:
The patent manages vector complexity by optimizing stuffer sequence parameters (length, composition, structure) rather than simply adding arbitrary non-coding sequences. This parameter optimization approach achieves packaging capacity goals while minimizing the introduction of unnecessary complexity.
Data Source
AI summary
The present invention relates to nucleic acid expression cassettes that are engineered to include polynucleotide sequences useful as inert stuffer (or filler) sequences in expression cassettes, particularly useful for transgene expression delivered as viral vectors, incorporating the engineered expression cassettes described herein, including rAA Vs, for use in therapy.